局部联合5-氟尿嘧啶与卡泊三醇治疗光化性角化病及浅表角质形成细胞癌:ITSCC改良Delphi专家小组建议
针对局部联合5-氟尿嘧啶/卡泊三醇(5-FU/C)治疗光化性角化病(AK)、原位鳞状细胞癌(SCCIS)和浅表基底细胞癌(sBCC)证据不足的问题,国际免疫抑制与移植皮肤癌协作组(ITSCC)通过改良Delphi法形成专家共识。专家组由9名皮肤科/皮肤外科医生组成,以70%或以上一致性作为共识标准,给出了AK、SCCIS、光化性唇炎及免疫抑制患者的5-FU/C治疗方案推荐。
要点
- AK面部/颈部5-FU/C每日2次用4-5天,头皮/躯干/四肢用7-10天。
- SCCIS面部/颈部每日2次用7-10天,头皮/躯干/四肢用10-14天。
- 光化性唇炎每日2次用4-5天,免疫抑制患者无需调整方案。
核心结论
- 皮肤科医生可考虑采用专家小组推荐的5-FU/C方案治疗AK、SCCIS和sBCC,同时等待更大规模高质量研究。
研究设计与样本
- 改良Delphi专家小组共识,由9名ITSCC皮肤科/皮肤外科成员参与,均具备>5年培训后经验或丰富5-FU/C处方经验。
- 专家组成员获得5-FU/C文献综述结果及ITSCC临床医生处方5-FU/C的调查结果。
- 共识标准为受访者间70%或以上一致性。
主要发现
- 专家组就AK、SCCIS、光化性唇炎及免疫抑制患者的5-FU/C治疗方案达成关键推荐。
- AK治疗:面部/颈部每日2次4-5天,头皮/躯干/四肢每日2次7-10天。
- SCCIS治疗:面部/颈部每日2次7-10天,头皮/躯干/四肢每日2次10-14天。
- 光化性唇炎治疗:每日2次4-5天。
- 免疫抑制患者无需调整治疗方案。
关键数值与推荐
- AK:5-FU/C每日2次,面部/颈部4-5天,头皮/躯干/四肢7-10天。
- SCCIS:5-FU/C每日2次,面部/颈部7-10天,头皮/躯干/四肢10-14天。
- 光化性唇炎:5-FU/C每日2次4-5天。
- 免疫抑制患者:无需调整治疗。
- 共识阈值:70%或以上一致性。
临床怎么用
- 皮肤科医生可参照专家共识对AK、SCCIS和sBCC使用5-FU/C局部联合治疗。
- 根据病变部位和类型选择相应的治疗时长。
- 免疫抑制患者使用5-FU/C无需调整方案。
局限性
- 专家小组规模小。
- 现有文献主要包含小型回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence on topical combined 5-fluorouracil/calcipotriene (5-FU/C) treatment of actinic keratoses (AKs), squamous cell carcinoma in situ (SCCIS), and superficial basal cell carcinoma is lacking. OBJECTIVE: To develop an expert consensus regarding 5-FU/C treatment of AKs, SCCIS, and superficial basal cell carcinoma. METHODS: Expert panelists were provided 5-FU/C literature review findings and survey results from International Immunosuppression and Transplant Skin Cancer Collaborative clinician members who prescribe 5-FU/C. RESULTS: Nine dermatologist/dermatologic surgeon International Immunosuppression and Transplant Skin Cancer Collaborative members with >5 years post-training experience or considerable clinical experience prescribing 5-FU/C participated in the panel. A 70% or higher concordance among respondents represented consensus. Key recommendations include: treating AKs with 5-FU/C twice daily for 4 to 5 days on the face/neck and 7 to 10 days on the scalp, trunk, and extremities; treating SCCIS with 5-FU/C twice daily for 7 to 10 days on the face/neck and 10 to 14 days on the scalp, trunk, and extremities; treating actinic cheilitis with 5-FU/C twice daily for 4 to 5 days; and no treatment modifications for patient immunosuppression. LIMITATIONS: Small panel size and literature to date primarily including small, retrospective studies. CONCLUSIONS: Dermatologists may consider implementation of expert panel recommendations for treatment of AKs, SCCIS, and sBCC with 5-FU/C while awaiting larger, high-quality studies.
引用
- Loranger N, Trepanowski N, Shah P, et al. Topical combined 5-fluorouracil and calcipotriene for actinic keratosis and superficial keratinocyte carcinoma: Modified Delphi expert panel recommendations from ITSCC. J Am Acad Dermatol. 2026. PMID: 41933793. doi:10.1016/j.jaad.2026.03.088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。